Results 71 to 80 of about 20,409 (197)

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 170-188, June 2026.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 107-116, June 2026.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

Some safety aspects of a new russian pegylated interferon-A medication “ALGERON” (phase 1 clinical trial)

RUDN Journal of Medicine, 2014
Treatment of hepatitis C is one of the most acute international healthcare problems. High standard in management of patients with HCV virus is combined therapy with pegylated interferon-a plus ribavirin.
A I Tukach, S B Fitilev, I I Shkrebniova, A V Vozzhaev, V A Yakushev, R A Ivanov, Yu N Lin’kova, T V Chernovskaya   +7 more
doaj  

Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review

Brazilian Journal of Infectious Diseases, 2014
Pegylated interferon alpha (Peg IFN-α) in combination with ribavirin is the backbone of treatment in chronic hepatitis C (CHC). Cardiotoxicity due to interferon therapy is rare.
Wenxue Zhao, Fanpu Ji, Shanshan Yu, Zongfang Li, Hong Deng   +4 more
doaj   +1 more source

Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa

Journal of Hepatology, 2010
Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USASee Article, pages 460–467Hepatitis C virus (HCV) infection affects approximately 170 mil-lion individuals worldwide [1,2].
Dimova, Rositsa B., Talal, Andrew H.
openaire   +2 more sources

Advances in mucosal injury mechanisms in radiation‐induced esophagitis associated with thoracic radiotherapy

Precision Radiation Oncology, Volume 10, Issue 2, Page 242-253, June 2026.
There is no specific therapeutic drug regimen for radiation esophagitis. In previous studies, radiation esophagitis was considered a self‐limiting disease; however, current clinical approaches are limited to symptomatic treatment, which yields unsatisfactory therapeutic outcomes.
Hao Zhang, Liangxue Luo, Chaofen Zhao, Bibo Wu, Jing Zhang, Lingfeng Liu, Bing Lu, Shengfa Su   +7 more
wiley   +1 more source

Test system for the detection of binding antibodies to interferon beta-1a for clinical use

Биопрепараты: Профилактика, диагностика, лечение, 2018
Test system for determining the presence of binding antibodies to interferon beta-1a (BAB to IFN beta-1a) in serum using ELISA has been developed.
E. A. Kuzminova, T. Yu. Ostroukhova, A. V. Grachev, E. L. Morozova   +3 more
doaj  

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, Volume 56, Issue 6, Page 903-913, June 2026.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

Pegylated Interferon Lambda for Covid-19

New England Journal of Medicine, 2023
Mingqiang, Wang, Lingling, Tang, Lingtong, Huang   +2 more
openaire   +4 more sources